HER3-DXd
Breast Cancer
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Bartsch R, Marhold M, Garde-Noguera J, et al.
Lancet Oncol 2025; 26: 1467–78.
Pipeline Compounds
Tumor-agnostic
DS-3939a: A TA-MUC1-directed antibody-drug conjugate with broad anti-tumor activity
Takano K, Yukiura M, Takahashi K, et al.
Mol Cancer Ther. 2025 Jul 10. doi: 10.1158/1535-7163.MCT-24-0666.
Pipeline Compounds
Hematology
Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells
Satoh K, Kobayashi Y, Fujimaki K, et al.
Int Immunol. 2021 Jul 23;33(8):435-446. doi: 10.1093/intimm/dxab027.
Pipeline Compounds
Hematology
Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma
Suzuki K, Kusayanagi S, Kuze Y, et al.
Leukemia. 2025 Oct;39(10):2465-2476. doi: 10.1038/s41375-025-02725-0.
HER3-DXd
Tumor-agnostic
HERTHENA-PanTumor01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors
Powles T, Bhatia A, Burtness B, et al.
Future Oncol. 2025;21(25):3283-3292. doi: 10.1080/14796694.2025.2561539.
I-DXd
Lung Cancer
Ifinatamab deruxtecan in patients with extensive-stage small-cell lung cancer: Primary analysis of the phase 2 IDeate-Lung01 trial
Rudin CM, Johnson ML, Paz-Ares L, et al.
J Clin Oncol. 2025 14:101200JCO2502142. doi: 10.1200/JCO-25-02142.
Valemetostat
Hematology
Physiologically based pharmacokinetic modeling of valemetostat to inform dose recommendations when coadministered with CYP3A/P-gp modulators
Watanabe A, Okudaira N, Tachibana M, et al.
Clin Transl Sci. 2025;18(10):e70333. doi: 10.1111/cts.70333.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: Long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Modi S, Jacot W, Iwata H, et al.
Nat Med. 2025. doi: 10.1038/s41591-025-03981-4.
I-DXd
Lung Cancer
IDeate-Lung02: A Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer
Owonikoko TK, Byers L, Cheng Y, et al.
Future Oncol. 2025;21(25):3275-3282. doi: 10.1080/14796694.2025.2565995.
Quizartinib
Hematology
FLT3-ITD measurable residual disease from the QuANTUM-First trial
Levis MJ, Erba HP, Montesinos P, et al.
Blood Adv. 2025:bloodadvances.2025016444. doi: 10.1182/bloodadvances.2025016444.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26